| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/03/2003 | US20030124513 RNA interfering molecule which modulates gene expression; human immunodeficiency virus (HIV); configurations; cleavage |
| 07/03/2003 | US20030124202 Formulations and methods for reducing skin irritation |
| 07/03/2003 | US20030124200 Sucralose, glucosamine and a beverage base, especially fruit juice; cartilage supplements include chondroitin, glucosamine, and hyaluronic acid |
| 07/03/2003 | US20030124196 Pulsatile release compositions and methods for enhanced intestinal drug absorption |
| 07/03/2003 | US20030124194 Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor |
| 07/03/2003 | US20030124193 Atomizing nozzles include a liquid nozzle adapted to disperse a supply of liquid and a gas nozzle adapted to disperse a supply of gas; spray drying at a commercial plant scale. |
| 07/03/2003 | US20030124191 Pharmaceutical or nutraceutical, surfactant, wetting agent and diluent; rapid release when contacted with mucosal surface |
| 07/03/2003 | US20030124190 Methods and compositions for treating pain of the mucous membrane |
| 07/03/2003 | US20030124189 Combination of chitosan and second polymer that are not covalently or ionically crosslinked, prepared by dissolving both polymers in an acidic aqueous solution, dehydrating and recovering |
| 07/03/2003 | US20030124188 Oral pulsed dose drug delivery system |
| 07/03/2003 | US20030124184 Liquiflash particles and an excipient mass; friability of less than 1%; need for conventional super disintegrant and having a friability of less than 1%; no need for conventional superdisintegrant |
| 07/03/2003 | US20030124182 Oral capsule formulation with increased physical stability |
| 07/03/2003 | US20030124179 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder |
| 07/03/2003 | US20030124177 Compositions and methods for transdermal oxybutynin therapy |
| 07/03/2003 | US20030124176 Use of a base in order to increase the flux of the active agent through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. |
| 07/03/2003 | US20030124151 Pamidronate solution |
| 07/03/2003 | US20030124139 Reduced aggregation and proteolytic breakdown; dissolution buffer comprising at least one amorphous excipient, at least one amorphous buffer, and at least one MenC immunogen |
| 07/03/2003 | US20030124131 Immunoconjugates of toxins directed against malignant cells |
| 07/03/2003 | US20030124127 Targeting leukemia cells |
| 07/03/2003 | US20030124119 Antibody is dissolved in a buffer solution containing as a buffer acetic acid, citric acid, phosphoric acid, and/or salts thereof and is a solution of pH 5 to 8. |
| 07/03/2003 | US20030124112 Containing lysozyme, tris(hydroxymethyl)aminomethane, and optionally ascorbic acid, and/or citric acid and/or ethylenediaminetetraacetic acid |
| 07/03/2003 | US20030124110 Use of modified lysozyme c to prepare medicinal compositions for the treatment of some serious diseases |
| 07/03/2003 | US20030124086 Polymer conjugates of opioid antagonists |
| 07/03/2003 | US20030124063 Premeasured single unit dose; may be free of anti-microbial preservatives, such as benzalkonium chloride. |
| 07/03/2003 | US20030124057 Complex of antibody and radionucleotide; therapy, medical diagnosis |
| 07/03/2003 | US20030124055 Immobilization to polymer; antitumor agents, rheumatic diseases, autoimmune disease |
| 07/03/2003 | US20030124048 Filler for adhesives, rubbers, cosmetics; precipitating, separation, drying |
| 07/03/2003 | US20030124033 Method and apparatus for liposome production |
| 07/03/2003 | DE29522419U1 Multiple unit tabletted dosage form contg omeprazole - comprising enteric coated layered units of core material contg omeprazole compressed with excipients into tablets |
| 07/03/2003 | CA2507870A1 Method of modulating release of saccharides and uses thereof |
| 07/03/2003 | CA2477563A1 Probe for mass spectrometry |
| 07/03/2003 | CA2471396A1 Ultrapure oral fludara formulation with a fast releasing active substance |
| 07/03/2003 | CA2471241A1 Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant |
| 07/03/2003 | CA2471096A1 Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| 07/03/2003 | CA2471081A1 Formulation & dosage form for the controlled delivery of therapeutic agents |
| 07/03/2003 | CA2470999A1 Syn3 compositions and methods |
| 07/03/2003 | CA2470992A1 Process for preparation of inclusion compounds between a non-steroidal anti-inflammatory drug and betacyclodextrin by microwave treatment |
| 07/03/2003 | CA2470976A1 Ph-sensitive polymeric conjugates of an anthracycline drug |
| 07/03/2003 | CA2470912A1 Pharmaceutical suspension for oral administration |
| 07/03/2003 | CA2470859A1 Pharmaceutical composition comprising skim milk powder |
| 07/03/2003 | CA2470857A1 Metered dose inhaler |
| 07/03/2003 | CA2470829A1 Particulate compositions |
| 07/03/2003 | CA2470776A1 Malleable protein matrix and uses thereof |
| 07/03/2003 | CA2470636A1 Zero-order sustained released dosage forms and method of making the same |
| 07/03/2003 | CA2470603A1 Methods for the treatment of peripheral neural and vascular ailments |
| 07/03/2003 | CA2470443A1 Pharmaceutical compositions based on azetidine derivatives |
| 07/03/2003 | CA2470364A1 Pharmaceutical composition for the treatment of psoriasis and other skin diseases |
| 07/03/2003 | CA2470316A1 Lyophilized preparation containing antibodies to the egf receptor |
| 07/03/2003 | CA2470003A1 Composition for treating contact lenses in the eye |
| 07/03/2003 | CA2469904A1 Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma |
| 07/03/2003 | CA2469894A1 Use of micro-organisms for a directed delivery of substances to specific parts of the gut |
| 07/03/2003 | CA2469047A1 Tempamine compositions and methods of use |
| 07/03/2003 | CA2468775A1 Heparin-containing ophthalmic agent |
| 07/03/2003 | CA2468627A1 Liposome composition for delivery of nucleic acid |
| 07/03/2003 | CA2466633A1 Sustained-release compositions |
| 07/03/2003 | CA2466617A1 Food or pet food composition containing plant extract for bone health |
| 07/03/2003 | CA2465890A1 Aqueous sustained-release formulations of proteins |
| 07/03/2003 | CA2451993A1 Polypeptide, its conjugate with doxorubicin and conjugate-based pharmaceutical composition |
| 07/02/2003 | EP1323731A1 Novel peptides |
| 07/02/2003 | EP1323433A1 Compositions for preventing urinary calculus |
| 07/02/2003 | EP1323432A1 Complexes of cyclodextrins with potassium ion homeostasis regulators |
| 07/02/2003 | EP1323431A2 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| 07/02/2003 | EP1323430A2 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| 07/02/2003 | EP1323417A1 Tablets quickly disintegrating in the oral cavity and process for producing the same |
| 07/02/2003 | EP1323404A1 Hard capsule |
| 07/02/2003 | EP1323346A2 Receptor specific transepithelial transport of immunogens |
| 07/02/2003 | EP1322755A1 Human and mouse targeting peptides identified by phage display |
| 07/02/2003 | EP1322673A1 Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative |
| 07/02/2003 | EP1322656A2 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 07/02/2003 | EP1322597A1 Process and intermediates |
| 07/02/2003 | EP1322595A2 (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents |
| 07/02/2003 | EP1322411A1 Colloidal suspension of submicronic particles for carrying active principles and their mode of preparation |
| 07/02/2003 | EP1322337A2 Pei : dna vector formulations for in vitro and in vivo gene delivery |
| 07/02/2003 | EP1322336A1 Method of increasing testosterone and related steroid concentrations in women |
| 07/02/2003 | EP1322329A1 Split enveloped virus preparation |
| 07/02/2003 | EP1322318A1 Use of probiotic lactic acid bacteria for balancing the skin's immune system |
| 07/02/2003 | EP1322302A2 Taxoid conjugates as antimitotic and antitumor agents |
| 07/02/2003 | EP1322300A1 Inhalation particles incorporating a combination of two or more active ingredients |
| 07/02/2003 | EP1322299A2 Composition for the transdermal delivery of fentanyl |
| 07/02/2003 | EP1322297A2 Chrono delivery formulations and method of use thereof |
| 07/02/2003 | EP1322296A1 Colloidal suspension of submicronic particles for carrying hydrophilic active principles (insulin) and method for preparing same |
| 07/02/2003 | EP1322293A1 Modified release formulation |
| 07/02/2003 | EP1322292A2 Microparticle compositions and methods for the manufacture thereof |
| 07/02/2003 | EP1322291A1 Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight |
| 07/02/2003 | EP1322290A1 Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight |
| 07/02/2003 | EP1322288A1 Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions |
| 07/02/2003 | EP1322287A2 Microparticles for delivery of the heterologous nucleic acids |
| 07/02/2003 | EP1322286A2 Polymeric delivery formulations of leuprolide with improved efficacy |
| 07/02/2003 | EP1322275A2 Ultrasonic method and device for wound treatment |
| 07/02/2003 | EP1322182A2 Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof |
| 07/02/2003 | EP1322158A1 Sustained release pharmaceutical compositions containing metformin and method of its production |
| 07/02/2003 | EP1263327A4 Biocompatible material composition adaptable to diverse therapeutic indications |
| 07/02/2003 | EP1146856B1 Spheronised self-emulsifying system for hydrophobic and water-sensitive agents |
| 07/02/2003 | EP1124539B1 Pharmaceutical formulation comprising omeprazole |
| 07/02/2003 | EP1041966B1 Pharmaceutical compositions comprising zafirlukast |
| 07/02/2003 | EP1017371B1 Controlled release of drugs delivered by sublingual or buccal administration |
| 07/02/2003 | EP1014954B1 Transdermal therapeutic system |
| 07/02/2003 | EP0954292B1 Pharmaceutical formulations with delayed drug release |
| 07/02/2003 | EP0894010B1 Denaturants for sympathomimetic amine salts |
| 07/02/2003 | EP0880530B1 Phosphatidyl oligoglycerols |